Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
This study from China first demonstrated finerenone decreased UACR with manageable safety in real-world DKD treatment. A triple regimen of RASi, SGLT2i, and finerenone may be a promising treatment strategy for lowering albuminuria and reducing hyperkalemia risk in advanced DKD patients.
Authors
- Jingying Zhou (ORCID: https://orcid.org/0000-0002-9740-6159)
- Ming Fang
- Chenjie Gu (ORCID: https://orcid.org/0000-0002-1339-4534)
- Xinwei Li (ORCID: https://orcid.org/0000-0002-7036-5422)
- Xianan Guo
- Kang Le (ORCID: https://orcid.org/0000-0002-1714-2377)
Institutions
- Dalian Medical University (CN)
- Dalian University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1080/0886022x.2024.2400541
- Citations
- 11
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 3.93